Literature DB >> 5822576

Chromatographic, ultracentrifugal, and related studies of fibrinogen "Baltimore".

M W Mosesson, E A Beck.   

Abstract

Chromatographic, ultracentrifugal, and related studies of the fibrinogen of a patient with a congenital disorder of fibrinogen (fibrinogen "Baltimore" have provided evidence of structural differences from normal.Diethylaminoethyl-cellulose (DEAE-cellulose) gradient elution chromatography demonstrated two major peaks in the elution pattern of fibrinogen Baltimore as was the case for normal fibrinogen. However, the first peak of fibrinogen Baltimore was somewhat broader and more symmetrical and was eluted significantly later in the chromatogram than the corresponding peak of normal fibrinogen. Additionally, in some elution patterns, a shoulder on the ascending limb of peak 1 was present, suggesting the presence of chromatographically "normal" fibrinogen. Thrombin time determinations of eluted column fractions from a chromatogram of propositus fibrinogen supported this conclusion by demonstrating that fibrinogen from the ascending portion of peak 1 behaved functionally more like normal than that later in the chromatogram. Chromatograms of mixtures of propositus and normal fibrinogen confirmed the ability of this technique to distinguish normal from Baltimore fibrinogen. Chromatograms of fibrinogen isolated from two affected daughters displayed the characteristic increased anionic binding of peak 1 fibrinogen. Sedimentation velocity experiments indicated that the S(o) (20, [unk]) of fibrinogen Baltimore was slightly greater (8.13S vs. 7.85S) than that of normal fraction I-4. Differences in concentration dependence (- 0.65 c vs. - 1.30 c for normal) of the sedimentation coefficient could be attributable in part to spatial conformational differences. Molecular sieving experiments in acrylamide gels indicated that the molecular weight of propositus fraction I-2 was about the same as that of normal fibrinogen of comparable solubility (i.e. I-4, mol wt 325,000). Studies of the UV spectra, tyrosine/tryptophan ratios, sialic acid and hexose content, and N-terminal amino acids demonstrated no consistent significant differences from normal fraction I-4.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5822576      PMCID: PMC535736          DOI: 10.1172/JCI106130

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore').

Authors:  E A Beck; P Charache; D P Jackson
Journal:  Nature       Date:  1965-10-09       Impact factor: 49.962

2.  Studies on fibrin monomer aggregation in congenital dysfibrinogenaemia (fibrinogen "Zürich"): separation of a pathological from a normal fibrin fraction.

Authors:  A von Felten; P G Frick; P W Straub
Journal:  Br J Haematol       Date:  1969-04       Impact factor: 6.998

3.  An inherited qualitative abnormality in plasma fibrinogen: fibrinogen Cleveland.

Authors:  W B Forman; O D Ratnoff; M H Boyer
Journal:  J Lab Clin Med       Date:  1968-09

4.  Congenital disorders of fibrinogen.

Authors:  D P Jackson; E A Beck; P Charache
Journal:  Fed Proc       Date:  1965 Jul-Aug

5.  Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility.

Authors:  M W Mosesson; N Alkjaersig; B Sweet; S Sherry
Journal:  Biochemistry       Date:  1967-10       Impact factor: 3.162

6.  The preparation and properties of human fibrinogen of relatively high solubility.

Authors:  M W Mosesson; S Sherry
Journal:  Biochemistry       Date:  1966-09       Impact factor: 3.162

7.  Familial disturbance of fibrin monomer aggregation.

Authors:  A Von Felten; F Duckert; P G Frick
Journal:  Br J Haematol       Date:  1966-11       Impact factor: 6.998

8.  [Hemorrhagic diathesis with dominant heredity, caused by an abnormal fibrinogen (fibrinogen Baltimore)].

Authors:  E A Beck; M W Mosesson; P Charache; D P Jackson
Journal:  Schweiz Med Wochenschr       Date:  1966-09-17

9.  Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen?

Authors:  M Blombäck; B Blombäck; E F Mammen; A S Prasad
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

10.  Congenital dysfibrinogenemia: fibrinogen Detroit.

Authors:  E F Mammen; A S Prasad; M I Barnhart; C C Au
Journal:  J Clin Invest       Date:  1969-02       Impact factor: 14.808

View more
  9 in total

1.  Studies on the structural abnormality of fibrinogen Paris I.

Authors:  M W Mosesson; D L Amrani; D Ménaché
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

2.  Congenital dysfibrinogenemias: molecular abnormalities of fibrinogen.

Authors:  E F Mammen
Journal:  Blut       Date:  1976-10

3.  [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].

Authors:  F R Matthias; W H Krause; S Ganssert; K Mueller; H G Lasch
Journal:  Klin Wochenschr       Date:  1977-06-01

Review 4.  Hereditary disorders of blood coagulation due to defective and deficient synthesis of protein.

Authors:  D P Jackson
Journal:  Trans Am Clin Climatol Assoc       Date:  1971

5.  Molecular deficiencies of human blood coagulation.

Authors:  E A Beck
Journal:  Experientia       Date:  1972-01-15

6.  Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".

Authors:  E A Beck; J R Shainoff; A Vogel; D P Jackson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

7.  Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.

Authors:  J Martinez; R R Holburn; S S Shapiro; A J Erslev
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

8.  Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.

Authors:  E D Crum; J R Shainoff; R C Graham; O D Ratnoff
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

9.  Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.

Authors:  H R Gralnick; H M Givelber; J R Shainoff; J S Finlayson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.